Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia

Jitesh D. Kawedia, Chengcheng Liu, Deqing Pei, Cheng Cheng, Christian A. Fernandez, Scott Howard, Dario Campana, John C. Panetta, W. Paul Bowman, William E. Evans, Ching Hon Pui, Mary V. Relling

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

We have previously hypothesized that higher systemic exposure to asparaginase may cause increased exposure to dexamethasone, both critical chemotherapeutic agents for acute lymphoblastic leukemia. Whether interpatient pharmacokinetic differences in dexamethasone contribute to relapse risk has never been studied. The impact of plasma clearance of dexamethasone and anti-asparaginase antibody levels on risk of relapse was assessed in 410 children who were treated on a front-line clinical trial for acute lymphoblastic leukemia and were evaluable for all pharmacologic measures, using multivariate analyses, adjusting for standard clinical and biologic prognostic factors. Dexamethasone clearance (mean ± SD) was higher (P = 3 × 10 -8 ) in patients whose sera was positive (17.7 ± 18.6 L/h per m 2 ) versus negative (10.6 ± 5.99 L/h per m 2 ) for anti-asparaginase antibodies. In multivariate analyses, higher dexamethasone clearance was associated with a higher risk of any relapse (P = .01) and of central nervous system relapse (P = .014). Central nervous system relapse was also more common in patients with anti-asparaginase antibodies (P = .019). In conclusion, systemic clearance of dexamethasone is higher in patients with anti-asparaginase antibodies. Lower exposure to both drugs was associated with an increased risk of relapse.

Original languageEnglish (US)
Pages (from-to)1658-1664
Number of pages7
JournalBlood
Volume119
Issue number7
DOIs
StatePublished - Feb 16 2012

Fingerprint

Asparaginase
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Dexamethasone
Recurrence
Antibodies
Anti-Idiotypic Antibodies
Neurology
Multivariate Analysis
Central Nervous System
Pharmacokinetics
Biological Factors
Clinical Trials
Plasmas
Serum
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Kawedia, J. D., Liu, C., Pei, D., Cheng, C., Fernandez, C. A., Howard, S., ... Relling, M. V. (2012). Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood, 119(7), 1658-1664. https://doi.org/10.1182/blood-2011-09-381731

Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. / Kawedia, Jitesh D.; Liu, Chengcheng; Pei, Deqing; Cheng, Cheng; Fernandez, Christian A.; Howard, Scott; Campana, Dario; Panetta, John C.; Bowman, W. Paul; Evans, William E.; Pui, Ching Hon; Relling, Mary V.

In: Blood, Vol. 119, No. 7, 16.02.2012, p. 1658-1664.

Research output: Contribution to journalArticle

Kawedia, JD, Liu, C, Pei, D, Cheng, C, Fernandez, CA, Howard, S, Campana, D, Panetta, JC, Bowman, WP, Evans, WE, Pui, CH & Relling, MV 2012, 'Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia', Blood, vol. 119, no. 7, pp. 1658-1664. https://doi.org/10.1182/blood-2011-09-381731
Kawedia, Jitesh D. ; Liu, Chengcheng ; Pei, Deqing ; Cheng, Cheng ; Fernandez, Christian A. ; Howard, Scott ; Campana, Dario ; Panetta, John C. ; Bowman, W. Paul ; Evans, William E. ; Pui, Ching Hon ; Relling, Mary V. / Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. In: Blood. 2012 ; Vol. 119, No. 7. pp. 1658-1664.
@article{0f2f8968d005446e802c921b58881de3,
title = "Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia",
abstract = "We have previously hypothesized that higher systemic exposure to asparaginase may cause increased exposure to dexamethasone, both critical chemotherapeutic agents for acute lymphoblastic leukemia. Whether interpatient pharmacokinetic differences in dexamethasone contribute to relapse risk has never been studied. The impact of plasma clearance of dexamethasone and anti-asparaginase antibody levels on risk of relapse was assessed in 410 children who were treated on a front-line clinical trial for acute lymphoblastic leukemia and were evaluable for all pharmacologic measures, using multivariate analyses, adjusting for standard clinical and biologic prognostic factors. Dexamethasone clearance (mean ± SD) was higher (P = 3 × 10 -8 ) in patients whose sera was positive (17.7 ± 18.6 L/h per m 2 ) versus negative (10.6 ± 5.99 L/h per m 2 ) for anti-asparaginase antibodies. In multivariate analyses, higher dexamethasone clearance was associated with a higher risk of any relapse (P = .01) and of central nervous system relapse (P = .014). Central nervous system relapse was also more common in patients with anti-asparaginase antibodies (P = .019). In conclusion, systemic clearance of dexamethasone is higher in patients with anti-asparaginase antibodies. Lower exposure to both drugs was associated with an increased risk of relapse.",
author = "Kawedia, {Jitesh D.} and Chengcheng Liu and Deqing Pei and Cheng Cheng and Fernandez, {Christian A.} and Scott Howard and Dario Campana and Panetta, {John C.} and Bowman, {W. Paul} and Evans, {William E.} and Pui, {Ching Hon} and Relling, {Mary V.}",
year = "2012",
month = "2",
day = "16",
doi = "10.1182/blood-2011-09-381731",
language = "English (US)",
volume = "119",
pages = "1658--1664",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",

}

TY - JOUR

T1 - Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia

AU - Kawedia, Jitesh D.

AU - Liu, Chengcheng

AU - Pei, Deqing

AU - Cheng, Cheng

AU - Fernandez, Christian A.

AU - Howard, Scott

AU - Campana, Dario

AU - Panetta, John C.

AU - Bowman, W. Paul

AU - Evans, William E.

AU - Pui, Ching Hon

AU - Relling, Mary V.

PY - 2012/2/16

Y1 - 2012/2/16

N2 - We have previously hypothesized that higher systemic exposure to asparaginase may cause increased exposure to dexamethasone, both critical chemotherapeutic agents for acute lymphoblastic leukemia. Whether interpatient pharmacokinetic differences in dexamethasone contribute to relapse risk has never been studied. The impact of plasma clearance of dexamethasone and anti-asparaginase antibody levels on risk of relapse was assessed in 410 children who were treated on a front-line clinical trial for acute lymphoblastic leukemia and were evaluable for all pharmacologic measures, using multivariate analyses, adjusting for standard clinical and biologic prognostic factors. Dexamethasone clearance (mean ± SD) was higher (P = 3 × 10 -8 ) in patients whose sera was positive (17.7 ± 18.6 L/h per m 2 ) versus negative (10.6 ± 5.99 L/h per m 2 ) for anti-asparaginase antibodies. In multivariate analyses, higher dexamethasone clearance was associated with a higher risk of any relapse (P = .01) and of central nervous system relapse (P = .014). Central nervous system relapse was also more common in patients with anti-asparaginase antibodies (P = .019). In conclusion, systemic clearance of dexamethasone is higher in patients with anti-asparaginase antibodies. Lower exposure to both drugs was associated with an increased risk of relapse.

AB - We have previously hypothesized that higher systemic exposure to asparaginase may cause increased exposure to dexamethasone, both critical chemotherapeutic agents for acute lymphoblastic leukemia. Whether interpatient pharmacokinetic differences in dexamethasone contribute to relapse risk has never been studied. The impact of plasma clearance of dexamethasone and anti-asparaginase antibody levels on risk of relapse was assessed in 410 children who were treated on a front-line clinical trial for acute lymphoblastic leukemia and were evaluable for all pharmacologic measures, using multivariate analyses, adjusting for standard clinical and biologic prognostic factors. Dexamethasone clearance (mean ± SD) was higher (P = 3 × 10 -8 ) in patients whose sera was positive (17.7 ± 18.6 L/h per m 2 ) versus negative (10.6 ± 5.99 L/h per m 2 ) for anti-asparaginase antibodies. In multivariate analyses, higher dexamethasone clearance was associated with a higher risk of any relapse (P = .01) and of central nervous system relapse (P = .014). Central nervous system relapse was also more common in patients with anti-asparaginase antibodies (P = .019). In conclusion, systemic clearance of dexamethasone is higher in patients with anti-asparaginase antibodies. Lower exposure to both drugs was associated with an increased risk of relapse.

UR - http://www.scopus.com/inward/record.url?scp=84863116322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863116322&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-09-381731

DO - 10.1182/blood-2011-09-381731

M3 - Article

VL - 119

SP - 1658

EP - 1664

JO - Blood

JF - Blood

SN - 0006-4971

IS - 7

ER -